The nonsteroidal MR antagonist finerenone reverses Western diet-induced kidney disease by regulating mitochondrial and lipid metabolism and inflammation
Komuraiah Myakala, Xiaoxin X. Wang, Nataliia V. Shults, Eleni Hughes, Patrícia de Carvalho Ribeiro, Rozhin Penjweini, Katie A. Link, Keely Barton, Ewa Krawczyk, Cheryl Clarkson‐Paredes, Anastas Popratiloff, Jay R. Knutson, L. Ashley Cowart, Moshe Levi
Abstract
Finerenone, a nonsteroidal mineralocorticoid receptor (MR) antagonist, has shown promise in protecting against kidney damage in obese, insulin-resistant mice. It effectively prevents albuminuria, inflammation, fibrosis, and mitochondrial dysfunction, while also restoring estrogen-related receptor-γ (ERRγ) expression. These results suggest that finerenone could play a key role in halting the progression of kidney disease by enhancing mitochondrial function and reducing harmful lipid accumulation, offering a potential therapeutic strategy for managing kidney complications in metabolic disorders.